retatrutide metabolic benefits vs Tirzepatide: Key Differences for Researchers Retatrutide—A Game Changer in Obesity
Description
And estimates suggest that GLP-1 sales will reach $100M by the end of the decade
For instance, the STEP 1 extension study found that participants regained about two-thirds of their lost weight within a year of stopping semaglutide
Members who engage with Nooms GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged
Long-term use is limited to about 12 months because it places a burden on the pancreas
More glucose enters working muscle
